Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP known ✓ | O00591 | 3/20 | 0.64 |
| ▸ | GABRD known ✓ | O14764 | 3/20 | 0.64 |
| ▸ | GABRA1 known ✓ | P14867 | 3/20 | 0.64 |
| ▸ | GABRB1 known ✓ | P18505 | 3/20 | 0.64 |
| ▸ | GABRG2 known ✓ | P18507 | 3/20 | 0.64 |
| ▸ | GABRB3 known ✓ | P28472 | 3/20 | 0.64 |
| ▸ | GABRA5 known ✓ | P31644 | 3/20 | 0.64 |
| ▸ | GABRA3 known ✓ | P34903 | 3/20 | 0.64 |
| ▸ | GABRA2 known ✓ | P47869 | 3/20 | 0.64 |
| ▸ | GABRB2 known ✓ | P47870 | 3/20 | 0.64 |
| ▸ | GABRA4 known ✓ | P48169 | 3/20 | 0.64 |
| ▸ | GABRE known ✓ | P78334 | 3/20 | 0.64 |
| ▸ | GABRA6 known ✓ | Q16445 | 3/20 | 0.64 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 3/20 | 0.64 |
| ▸ | GABRG3 known ✓ | Q99928 | 3/20 | 0.64 |
| ▸ | GABRQ known ✓ | Q9UN88 | 3/20 | 0.64 |
| ▸ | XDH known ✓ | P47989 | 2/20 | 0.64 |
| ▸ | NR3C1 known ✓ | P04150 | 1/20 | 0.64 |
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.64 |
| ▸ | CA12 known ✓ | O43570 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10602000 | 0.91 | ABCB1 (0.64) | CREB1FLT3PRSS1PRSS2PRSS3 | |
| Baicalein SCHEMBL11094929 | 0.85 | ABCB1 (0.84) | CREB1FLT3PRSS1PRSS2PRSS3 | |
| Oroxylin A SCHEMBL431423 | 0.83 | CREB1 (1.00) | CREB1FLT3PRSS1PRSS2PRSS3 | |
| Oroxylin A SCHEMBL30452350 | 0.83 | CREB1 (1.00) | CREB1FLT3PRSS1PRSS2PRSS3 | |
| SCHEMBL738096 | 0.82 | CREB1 (0.69) | CREB1FLT3PRSS1PRSS2PRSS3 | |
| SCHEMBL971997 | 0.81 | CREB1 (0.75) | CREB1FLT3PRSS1PRSS2PRSS3 | |
| SCHEMBL972514 | 0.81 | CREB1 (1.00) | CREB1FLT3PRSS1PRSS2PRSS3 | |
| SCHEMBL972407 | 0.80 | CREB1 (1.00) | CREB1FLT3PRSS1PRSS2PRSS3 | |
| SCHEMBL971995 | 0.80 | CREB1 (1.00) | CREB1FLT3PRSS1PRSS2PRSS3 | |
| SCHEMBL738706 | 0.80 | CREB1 (0.72) | CREB1FLT3PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023067251-A1 | COMPOSITION FOR USE IN THE CUTANEOUS SYNTHESIS OF HYALURONIC ACID, IN AN IMMUNO-CUTANEOUS RESPONSE AND TO IMPROVE SKIN | JR (FR) | 2023-04-27 | — | — | WO | disclosed |
| US-8138165-B2 | Chromones and chromone derivatives and uses thereof | JENKEN BIOSCIENCES, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| EP-1556031-A4 | CHROMONES AND CHROMONE DERIVATIVES AND USES THEREOF | JENKEN BIOSCIENCES INC (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20060142211-A1 | Chromones and chromone derivatives and uses thereof | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2006-06-29 | — | — | US | disclosed |
| EP-1556031-A2 | CHROMONES AND CHROMONE DERIVATIVES AND USES THEREOF | Jenken Bioscience, Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004037193-A2 | CHROMONES AND CHROMONE DERIVATIVES AND USES THEREOF | JENKEN BIOSCIENCES, INC. (US) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142211-A1 | Chromones and chromone derivatives and uses thereof | PROC, HMGB1, PYCARD | GABRP 4406/4885GABRD 4855/4885GABRA1 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.